Related Experiment Video
Updated: Aug 20, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
Role of the gut microbiome in multiple sclerosis: From etiology to therapeutics
Shailesh K Shahi1, Meeta Yadav1, Sudeep Ghimire1
1Department of Pathology, University of Iowa, Iowa City, IA, United States; Iowa City VA Health System, Iowa City, IA, United States.
Abstract:
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS that affects around one million people in the United States. Predisposition or protection from this disease is linked with both genetic and environmental factors. In recent years, gut microbiome has emerged as an important environmental factor in the pathobiology of MS. The gut microbiome supports various physiologic functions, including the development and maintenance of the host immune system, the perturbation of which is known as dysbiosis and has been linked with multiple diseases including MS. We and others have shown that people with MS (PwMS) have gut dysbiosis that is characterized by specific gut bacteria being enriched or depleted. Consequently, there is an emphasis on determining the mechanism(s) through which gut bacteria and/or their metabolites alter the course of MS through their ability to provide protection, predispose individuals, or promote disease progression. Improving our understanding of these mechanisms will allow us to harness the enormous potential of the gut microbiome as a diagnostic and/or therapeutic agent. In this chapter, we will discuss current advances in microbiome research in the context of MS, including a review of specific bacteria that are currently linked with this disease, potential mechanisms of disease pathogenesis, and the utility of microbiome-based therapy for PwMS.
Insights
The gut microbiome influences multiple sclerosis (MS) development and progression. Research shows imbalances in gut bacteria (dysbiosis) in people with MS, highlighting potential diagnostic and therapeutic targets.
Area of Science:
- Neuroimmunology
- Microbiome Research
- Chronic Inflammatory Diseases
Background:
- Multiple sclerosis (MS) is a chronic central nervous system (CNS) inflammatory disease affecting approximately one million people in the US.
- Both genetic and environmental factors contribute to MS predisposition and protection.
- The gut microbiome, crucial for immune system development, is increasingly recognized as a significant environmental factor in MS pathobiology.
Approach:
- Investigating the link between gut dysbiosis and MS.
- Analyzing specific bacterial enrichments and depletions in people with MS (PwMS).
- Exploring mechanisms by which gut bacteria and their metabolites influence MS pathogenesis.
Key Points:
- Gut dysbiosis, an altered gut microbiome composition, is observed in PwMS.
- Specific gut bacteria are linked to MS, potentially promoting or protecting against the disease.
- Understanding these microbial mechanisms is key to developing microbiome-based diagnostics and therapies.
Conclusions:
- The gut microbiome plays a critical role in the pathobiology of MS.
- Targeting the gut microbiome offers potential for novel diagnostic and therapeutic strategies for MS.
- Further research into microbiome-MS interactions is essential for advancing treatment options.
Related Concept Videos
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Microorganisms in Medicine and Therapeutics
Physiology of Enteric Nervous System and Gut Health
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

